Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T 2A3, Canada.
British Columbia Cancer Research Centre, Vancouver, BC, Canada.
Mol Imaging Biol. 2019 Dec;21(6):1107-1116. doi: 10.1007/s11307-019-01331-8.
The system x transporter is upregulated in cancer cells in response to oxidative stress (OS). 5-[F]fluoroaminosuberic acid ([F]FASu) has been reported as a novel positron emission tomography (PET) imaging agent, targeting system x. The goal of this study was to evaluate the utility of [F]FASu in monitoring cellular response to diethyl maleate (DEM) and radiation-induced OS fluctuations.
[F]FASu uptake by breast cancer cells was studied in correlation to OS biomarkers: glutathione (GSH) and reactive oxygen species (ROS), as well as transcriptional and translational levels of xCT (the functional subunit of x). System x inhibitor, sulfasalazine (SSZ), and small interfering RNA (siRNA) knockdown were used as negative controls. Radiotracer uptake was evaluated in three breast cancer models: MDA-MB-231, MCF-7, and ZR-75-1, at two-time points (1 h and 16 h) following OS induction. In vivo [F]FASu imaging and biodistribution were performed using MDA-MB-231 xenograft-bearing mice at 16 and 24 h post-radiation treatment.
[F]FASu uptake was positively correlated to intracellular GSH and SLC7A11 expression levels, and radiotracer uptake was induced both by radiation treatment and by DEM at time points longer than 3 h. In an in vivo setting, there was no statistically significant uptake difference between irradiated and control tumors.
[F]FASu is a specific system x PET radiotracer and as such it can be used to monitor system x activity due to OS. As such, [F]FASu has the potential to be used in therapy response monitoring by PET. Further optimization is required for in vivo application.
系统 x 转运体在癌细胞中对氧化应激(OS)上调。5-[F]氟氨基琥珀酸([F]FASu)已被报道为一种新的正电子发射断层扫描(PET)成像剂,靶向系统 x。本研究的目的是评估 [F]FASu 监测二乙基马来酸(DEM)和辐射诱导 OS 波动引起的细胞反应的效用。
研究了 [F]FASu 在乳腺癌细胞中的摄取与 OS 生物标志物的相关性:谷胱甘肽(GSH)和活性氧(ROS),以及 xCT(系统 x 的功能亚基)的转录和翻译水平。使用磺酰胺(SSZ)和小干扰 RNA(siRNA)敲低作为阴性对照的系统 x 抑制剂。在三个乳腺癌模型中评估了放射性示踪剂摄取:MDA-MB-231、MCF-7 和 ZR-75-1,在 OS 诱导后两个时间点(1 小时和 16 小时)。在 MDA-MB-231 异种移植瘤荷瘤小鼠中,在辐射治疗后 16 和 24 小时进行了体内 [F]FASu 成像和生物分布。
[F]FASu 的摄取与细胞内 GSH 和 SLC7A11 表达水平呈正相关,并且在 3 小时以上的时间点,放射性示踪剂摄取既由辐射处理诱导,也由 DEM 诱导。在体内环境中,辐射和对照肿瘤之间没有统计学上的摄取差异。
[F]FASu 是一种特异性的系统 x PET 放射性示踪剂,因此它可用于监测由于 OS 引起的系统 x 活性。因此,[F]FASu 有可能通过 PET 用于治疗反应监测。需要进一步优化体内应用。